Cangrelor, an intravenous potent, rapid-acting P2Y12 inhibitor, reduces the risk of early ischemic events compared with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention, investigators reported during ACC.11, the American College of Cardiology’s 60th Annual Scientific Sessions.
Ticagrelor demonstrated comparable efficacy and safety compared with clopidogrel in elderly patients with acute coronary syndrome who are at higher risk for recurrent ischemic events, death, and treatment-related complications, according to study data presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Supratherapeutic plasma levels of dabigatran etexilate do not prolong QTc intervals of the electrocardiogram (ECG), as reported from a study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Addressing vitamin D deficiency may improve cardiovascular health, according to data presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
New recommendations are indicated for the treatment of extracranial carotid and vertebral artery disease (ECVD), UA/NSTEMI, and hypertrophic cardiomyopathy (HCM), according to several researchers who discussed the recent 2011 changes to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines at a symposium during ACC.11, the American College of Cardiology’s 60th Scientific Session.
At ACC.11, the American College of Cardiology’s 60th Annual Scientific Session, leading cardiologists discussed the changing landscape of atrial fibrillation (AF) management due to the availability and development of novel antiarrhythmic agents and new evidence supporting the use of anti-inflammatory drugs.
Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but demonstrates weaker safety outcomes, according to results of the MAGELLAN trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Six months of antiplatelet therapy is equivalent to the 12-month regimen that guidelines currently recommend for patients with drug-eluting stents, according to data from the EXCELLENT study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are equally effective at improving cardiovascular outcomes in patients with hypertension and glucose intolerance, according to results of the NAGOYA Heart Study, the first randomized study to compare the two drug classes presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Elderly patients with hypertension have similar rates of cardiovascular events and death when treated with a combination of an angiotensin II receptor blockers (ARB) and a calcium channel blocker (CCB), according to the results of a subanalysis of the OSCAR study that were presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.
Please login or register first to view this content.
